ArticleFrontiers in immunology2025
Emu-miR-10a-5p in
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Human leukocyte extract enhances albendazole efficacy against Echinococcus multilocularis in mice by reducing parasitic microRNAs, myeloid and lymphoid immunosuppressive cells.PLoS neglected tropical diseases · 2026Article
- Notoginsenoside R1 Alleviates Macrophage Inflammatory Responses via Modulating the JAK1/STAT3 Pathway.Journal of cellular biochemistry · 2026Article
- Identification and multi-omics analysis of extracellular vesicles from the plerocercoids of Spirometra mansoni (Cestoda: Diphyllobothriidae).Parasitology research · 2026Article
- Polarization of Hepatic Macrophages in Alveolar Echinococcosis and Its Role in Remodeling the Immune Microenvironment.Tropical medicine and infectious disease · 2026Review
- Exploring the Potential Value of Inflammatory Response-Associated Genes in Chronic Rhinosinusitis with Nasal Polyps: An Integrated Bioinformatics and Experimental Validation Analysis.Journal of inflammation research · 2026Article
- Targeting the Epithelial Alarmin Axis with Biomedical Nanoparticles: A New Frontier in Allergic Asthma Therapy.International journal of nanomedicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Parasites and parasite-derived extracellular vesicles (EVs) and microRNAs (miRNAs) can protect against inflammatory diseases, such as asthma. M2a macrophages facilitate the development of allergic asthma. miR-10a-5p is closely associated with asthma, and emu-miR-10a-5p (encapsulated in Methods: We purified EVs by centrifugation, and characterized the EVs via nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). We used MH-S cells to construct the M2a polarization model. The gene expression changes in MH-S cells after transfect with emu-miR-10a-5p mimics was analyzed through transcriptome sequencing. We established a mouse model of ovalbumin (OVA)-induced allergic asthma. Hematoxylin and eosin (H&E), Masson's trichrome, and periodic acid-Schiff (PAS) staining were used to detect airway inflammation in the lung tissues. RT-qPCR, flow cytometry and Western Blot assays were performed to validate the expression of related genes and proteins. Results: Here, we observed that Discussion: These findings suggest that emu-miR-10a-5p encapsulated in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.